New drug SY-9453 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study is testing a new oral drug, SY-9453, in 122 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals are to check safety, find the best dose, and get a first look at whether the drug can shrink tumors. Participants must…
Phase: PHASE1 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC